NUTRA PHARMA CORP (NPHC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 150K 300K 450K Q3 '21: 86.9K Q4 '21: 97.7K Q1 '22: 89.5K Q2 '22: 87.4K Q3 '22: 92.8K Q4 '22: 145.8K Q1 '23: 186.6K Q2 '23: 210.5K Q3 '23: 237.5K Q4 '23: 205.6K Q1 '24: 188.8K Q2 '24: 188.1K Q3 '24: 211.5K Q4 '24: 246.3K Q1 '25: 282.6K Q2 '25: 315.4K Q3 '25: 310.6K Q4 '25: 257.6K Q1 '26: 210.9K Q2 '26: 160.8K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 200K 400K 600K Q3 '16: 141.2K Q4 '17: 94.1K Q1 '18: 111.5K Q2 '18: 102.1K Q3 '18: 75K Q4 '22: 249K Q1 '23: 344.3K Q2 '23: 399.4K Q3 '23: 446.2K Q4 '23: 396.5K Q1 '24: 328.6K Q2 '24: 298.8K Q3 '24: 254.5K Q4 '24: 247.3K Q1 '25: 271.3K Q2 '25: 279.8K Q3 '25: 273.7K Q4 '25: 196.6K Q1 '26: 156.5K Q2 '26: 125.7K Q4 '17 Q3 '18 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income TTM

-2.1M -1.4M -700K 0 700K 1.4M 2.1M Q3 '21: -1.8M Q4 '21: -2M Q1 '22: -1.8M Q2 '22: -1.7M Q3 '22: -1.4M Q4 '22: -1.9M Q1 '23: -2M Q2 '23: -1.8M Q3 '23: -1.8M Q4 '23: -887K Q1 '24: -783.6K Q2 '24: -820.8K Q3 '24: -839.8K Q4 '24: -878.4K Q1 '25: -932.9K Q2 '25: -1M Q3 '25: -1.2M Q4 '25: -1.5M Q1 '26: -1.5M Q2 '26: -1.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-18M -9M 0 9M 18M 27M Q3 '21: -17.3M Q4 '21: -13.1M Q1 '22: 25.9M Q2 '22: 21.9M Q3 '22: 7.1M Q4 '22: 8.2M Q1 '23: 2.6M Q2 '23: 2.9M Q3 '23: 2.1M Q4 '23: -1.4M Q1 '24: -1.2M Q2 '24: -1.3M Q3 '24: -1.3M Q4 '24: -1.3M Q1 '25: -2.3M Q2 '25: -1.5M Q3 '25: -1.8M Q4 '25: -2M Q1 '26: -1.1M Q2 '26: -5.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 80K 160K 240K Q3 '19: 36.3K Q4 '21: 41.3K Q1 '22: 50K Q2 '22: 101.8K Q3 '22: 133.2K Q4 '22: 162.8K Q1 '23: 200.4K Q2 '23: 219.8K Q3 '23: 203.6K Q4 '23: 177.5K Q1 '24: 148.1K Q2 '24: 86.5K Q3 '24: 85.4K Q4 '24: 84.8K Q1 '25: 108.6K Q2 '25: 148.7K Q3 '25: 159K Q4 '25: 205.1K Q1 '26: 188.1K Q2 '26: 154.6K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-2.1M -1.4M -700K 0 700K 1.4M 2.1M Q3 '21: -1.9M Q4 '21: -1.7M Q1 '22: -1.4M Q2 '22: -1.2M Q3 '22: -942.1K Q4 '22: -762.4K Q1 '23: -597K Q2 '23: -499K Q3 '23: -417.8K Q4 '23: -550K Q1 '24: -628.5K Q2 '24: -535.2K Q3 '24: -432K Q4 '24: -424K Q1 '25: -657.8K Q2 '25: -852.5K Q3 '25: -1.1M Q4 '25: -1.2M Q1 '26: -1.1M Q2 '26: -1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-2.1M -1.4M -700K 0 700K 1.4M 2.1M Q2 '12: -1.1M Q3 '12: -545.4K Q4 '12: -721.2K Q1 '13: -587.2K Q3 '15: -887.3K Q4 '15: -1M Q4 '21: -1.8M Q1 '22: -1.5M Q2 '22: -1.3M Q3 '22: -1M Q4 '22: -820.4K Q4 '25: -1.2M Q3 '12 Q1 '13 Q4 '15 Q1 '22 Q3 '22 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15B 30B 45B Q1 '20: 12.3B Q2 '20: 6.6B Q3 '20: 13.1B Q1 '21: 7.1B Q2 '21: 11.8B Q3 '21: 12.7B Q1 '22: 14.5B Q2 '22: 7.5B Q3 '22: 15.6B Q1 '23: 7.6B Q2 '23: 7.6B Q3 '23: 7.6B Q1 '24: 7.6B Q2 '24: 7.7B Q3 '24: 7.7B Q1 '25: 7.7B Q2 '25: 37.7B Q3 '25: 7.8B Q1 '26: 8B Q2 '26: 8.1B Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

0.00 Q3 '21: 0.00 Q4 '21: 0.00 Q1 '22: 0.00 Q2 '22: 0.00 Q3 '22: 0.00 Q4 '22: 0.00 Q1 '23: 0.00 Q2 '23: 0.00 Q3 '23: 0.00 Q4 '23: 0.00 Q1 '24: 0.00 Q2 '24: 0.00 Q3 '24: 0.00 Q4 '24: 0.00 Q1 '25: 0.00 Q2 '25: 0.00 Q3 '25: 0.00 Q4 '25: 0.00 Q1 '26: 0.00 Q2 '26: 0.00 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.